242 related articles for article (PubMed ID: 23905594)
1. Renal nerve ablation for hypertensive patients with chronic kidney disease.
Papademetriou V; Doumas M; Anyfanti P; Faselis C; Kokkinos P; Tsioufis C
Curr Vasc Pharmacol; 2014 Jan; 12(1):47-54. PubMed ID: 23905594
[TBL] [Abstract][Full Text] [Related]
2. Number of ablated spots in the course of renal sympathetic denervation in CKD patients with uncontrolled hypertension: EnligHTN vs. Standard irrigated cardiac ablation catheter.
Kiuchi MG; Chen S; Rodrigues Paz LM; Pürerfellner H
Hipertens Riesgo Vasc; 2018; 35(2):54-63. PubMed ID: 28784273
[TBL] [Abstract][Full Text] [Related]
3. Resistant hypertension: is renal denervation the current treatment of choice?
Reddi AS
Clin Exp Hypertens; 2014; 36(8):525-30. PubMed ID: 24678737
[TBL] [Abstract][Full Text] [Related]
4. The pathophysiological basis of renal nerve ablation for the treatment of hypertension.
Ziakas A; Gossios T; Doumas M; Karali K; Megarisiotou A; Stiliadis I
Curr Vasc Pharmacol; 2014 Jan; 12(1):23-9. PubMed ID: 23905601
[TBL] [Abstract][Full Text] [Related]
5. Sustained Decrease in Blood Pressure and Reduced Anatomical and Functional Reinnervation of Renal Nerves in Hypertensive Sheep 30 Months After Catheter-Based Renal Denervation.
Singh RR; McArdle ZM; Iudica M; Easton LK; Booth LC; May CN; Parkington HC; Lombardo P; Head GA; Lambert G; Moritz KM; Schlaich MP; Denton KM
Hypertension; 2019 Mar; 73(3):718-727. PubMed ID: 30661475
[TBL] [Abstract][Full Text] [Related]
6. Chronic kidney disease: role of sympathetic nervous system activation and potential benefits of renal denervation.
Hering D; Esler MD; Schlaich MP
EuroIntervention; 2013 May; 9 Suppl R():R127-35. PubMed ID: 23732145
[TBL] [Abstract][Full Text] [Related]
7. The role of renal nerve ablation for the management of resistant hypertension and other disease conditions: benefits and concerns.
Faselis C; Doumas M; Kokkinos P; Tsioufis C; Papademetriou V
Curr Vasc Pharmacol; 2014 Jan; 12(1):38-46. PubMed ID: 23905598
[TBL] [Abstract][Full Text] [Related]
8. Renal denervation: current implications and future perspectives.
Xu J; Hering D; Sata Y; Walton A; Krum H; Esler MD; Schlaich MP
Clin Sci (Lond); 2014 Jan; 126(1):41-53. PubMed ID: 24020446
[TBL] [Abstract][Full Text] [Related]
9. Renal sympathetic denervation and renal physiology.
Kalaitzidis RG; Karasavvidou D; Siamopoulos KC
Curr Clin Pharmacol; 2013 Aug; 8(3):189-96. PubMed ID: 23173964
[TBL] [Abstract][Full Text] [Related]
10. Effects of renal denervation with a standard irrigated cardiac ablation catheter on blood pressure and renal function in patients with chronic kidney disease and resistant hypertension.
Kiuchi MG; Maia GL; de Queiroz Carreira MA; Kiuchi T; Chen S; Andrea BR; Graciano ML; Lugon JR
Eur Heart J; 2013 Jul; 34(28):2114-21. PubMed ID: 23786861
[TBL] [Abstract][Full Text] [Related]
11. Sympathetic activation secondary to chronic kidney disease: therapeutic target for renal denervation?
de Beus E; de Jager R; Joles JA; Grassi G; Blankestijn PJ
J Hypertens; 2014 Sep; 32(9):1751-61. PubMed ID: 24805954
[TBL] [Abstract][Full Text] [Related]
12. Renal Denervation to Modify Hypertension and the Heart Failure State.
Zhong M; Kim LK; Swaminathan RV; Feldman DN
Interv Cardiol Clin; 2017 Jul; 6(3):453-464. PubMed ID: 28600097
[TBL] [Abstract][Full Text] [Related]
13. Safety and performance of the second generation EnligHTN™ Renal Denervation System in patients with drug-resistant, uncontrolled hypertension.
Worthley SG; Wilkins GT; Webster MW; Montarello JK; Delacroix S; Whitbourn RJ; Warren RJ
Atherosclerosis; 2017 Jul; 262():94-100. PubMed ID: 28531827
[TBL] [Abstract][Full Text] [Related]
14. Modulation of Sympathetic Overactivity to Treat Resistant Hypertension.
Voora R; Hinderliter AL
Curr Hypertens Rep; 2018 Sep; 20(11):92. PubMed ID: 30194545
[TBL] [Abstract][Full Text] [Related]
15. [Renal denervation - a novel therapeutic option for resistant hypertension?].
Ritter A; Sudano Noll I; Suter PM
Praxis (Bern 1994); 2014 Oct; 103(20):1169-78. PubMed ID: 25270745
[No Abstract] [Full Text] [Related]
16. Expanding the indication spectrum: renal denervation in diabetes.
Mahfoud F; Ewen S; Ukena C; Linz D; Sobotka PA; Cremers B; Böhm M
EuroIntervention; 2013 May; 9 Suppl R():R117-21. PubMed ID: 23732142
[TBL] [Abstract][Full Text] [Related]
17. The Potential Role of Catheter-Based Renal Sympathetic Denervation in Chronic and End-Stage Kidney Disease.
Sata Y; Schlaich MP
J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):344-52. PubMed ID: 26740184
[TBL] [Abstract][Full Text] [Related]
18. The role of sympathetic nervous system in the progression of chronic kidney disease in the era of catheter based sympathetic renal denervation.
Petras D; Koutroutsos K; Kordalis A; Tsioufis C; Stefanadis C
Curr Clin Pharmacol; 2013 Aug; 8(3):197-205. PubMed ID: 23173962
[TBL] [Abstract][Full Text] [Related]
19. Acute effect of renal sympathetic denervation on blood pressure in refractory hypertensive patients with chronic kidney disease.
Kiuchi MG; Chen S; Graciano ML; Carreira MA; Kiuchi T; Andrea BR; Lugon JR
Int J Cardiol; 2015; 190():29-31. PubMed ID: 25912114
[No Abstract] [Full Text] [Related]
20. The future of interventional management of hypertension: threats and opportunities.
Briasoulis A; Bakris G
Curr Vasc Pharmacol; 2014 Jan; 12(1):69-76. PubMed ID: 23905592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
